Table of Contents
Hepatitis Research and Treatment
Volume 2011, Article ID 713216, 7 pages
http://dx.doi.org/10.1155/2011/713216
Review Article

Dysfunction of Immune Systems and Host Genetic Factors in Hepatitis C Virus Infection with Persistent Normal ALT

Division of Gastroenterology, Tohoku University Hospital, 1-1 Seiryo-Machi, Aoba-ku, Sendai City, Miyagi 980-8574, Japan

Received 2 March 2011; Accepted 15 April 2011

Academic Editor: Rodrigo Zapata

Copyright © 2011 Yasuteru Kondo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. J. Alter, D. Kruszon-Moran, O. V. Nainan et al., “The prevalence of hepatitis C virus infection in the United States, 1988 through 1994,” The New England Journal of Medicine, vol. 341, no. 8, pp. 556–562, 1999. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. P. Marcellin, S. Levy, and S. Erlinger, “Therapy of hepatitis C: patients with normal aminotransferase levels,” Hepatology, vol. 26, no. 3 supplement 1, pp. 133S–136S, 1997. View at Google Scholar
  3. N. C. Tassopoulos, “Treatment of patients with chronic hepatitis C and normal ALT levels,” Journal of Hepatology, vol. 31, no. 1, Supplement 1, pp. 193–196, 1999. View at Google Scholar · View at Scopus
  4. R. Zapata, “Clinical approach to the patient with chronic hepatitis C infection and normal aminotransferases,” Annals of Hepatology, vol. 9, pp. 72–79, 2010. View at Google Scholar
  5. C. Puoti, L. Bellis, A. Galossi et al., “Antiviral treatment of HCV carriers with persistently normal ALT levels,” Mini-Reviews in Medicinal Chemistry, vol. 8, no. 2, pp. 150–152, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. C. Puoti, L. Bellis, R. Castellacci et al., “Viral kinetics during antiviral therapy in patients with chronic hepatitis C and persistently normal ALT levels,” Hepatology, vol. 41, no. 3, pp. 683–684, 2005. View at Publisher · View at Google Scholar · View at PubMed
  7. M. Persico, E. Persico, R. Suozzo et al., “Natural history of hepatitis C virus carriers with persistently normal aminotransferase levels,” Gastroenterology, vol. 118, no. 4, pp. 760–764, 2000. View at Google Scholar · View at Scopus
  8. K. M. Chang, B. Rehermann, and F. V. Chisari, “Immunopathology of hepatitis C,” Springer Seminars in Immunopathology, vol. 19, no. 1, pp. 57–68, 1997. View at Publisher · View at Google Scholar · View at Scopus
  9. D. Accapezzato, V. Francavilla, M. Paroli et al., “Hepatic expansion of a virus-specific regulatory CD8+ T cell population in chronic hepatitis C virus infection,” Journal of Clinical Investigation, vol. 113, no. 7, pp. 963–972, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. T. Manigold and V. Racanelli, “T-cell regulation by CD4 regulatory T cells during hepatitis B and C virus infections: facts and controversies,” Lancet Infectious Diseases, vol. 7, no. 12, pp. 804–813, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. S. D. Blackburn and E. J. Wherry, “IL-10, T cell exhaustion and viral persistence,” Trends in Microbiology, vol. 15, no. 4, pp. 143–146, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. S. D. Blackburn, A. Crawford, H. Shin, A. Polley, G. J. Freeman, and E. J. Wherry, “Tissue-specific differences in PD-1 and PD-L1 expression during chronic viral infection: implications for CD8 T-cell exhaustion,” Journal of Virology, vol. 84, no. 4, pp. 2078–2089, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. Z. Q. Yao, D. Prayther, C. Trabue, Z. P. Dong, and J. Moorman, “Differential regulation of SOCS-1 signalling in B and T lymphocytes by hepatitis C virus core protein,” Immunology, vol. 125, no. 2, pp. 197–207, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. Y. Kondo, V. M. H. Sung, K. Machida, M. Liu, and M. M. C. Lai, “Hepatitis C virus infects T cells and affects interferon-γ signaling in T cell lines,” Virology, vol. 361, no. 1, pp. 161–173, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. Y. Kondo, K. Machida, H. M. Liu et al., “Hepatitis C virus infection of T cells inhibits proliferation and enhances Fas-mediated apoptosis by down-regulating the expression of CD44 splicing variant 6,” Journal of Infectious Diseases, vol. 199, no. 5, pp. 726–736, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. Y. Kondo, Y. Ueno, E. Kakazu et al., “Lymphotropic HCV strain can infect human primary naïve CD4+ cells and affect their proliferation and IFN-γ secretion activity,” Journal of Gastroenterology, vol. 46, no. 2, pp. 232–241, 2011. View at Publisher · View at Google Scholar · View at PubMed
  17. K. Machida, Y. Kondo, J. Y. Huang et al., “Hepatitis C virus (HCV)-induced immunoglobulin hypermutation reduces the affinity and neutralizing activities of antibodies against HCV envelope protein,” Journal of Virology, vol. 82, no. 13, pp. 6711–6720, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. M. Jinushi, T. Takehara, T. Kanto et al., “Critical role of MHC class I-related chain A and B expression on IFN-α-stimulated dendritic cells in NK cell activation: impairment in chronic hepatitis C virus infection,” Journal of Immunology, vol. 170, no. 3, pp. 1249–1256, 2003. View at Google Scholar · View at Scopus
  19. T. Kanto, N. Hayashi, T. Takehara et al., “Impaired allostimulatory capacity of peripheral blood dendritic cells recovered from hepatitis C virus-infected individuals,” Journal of Immunology, vol. 162, no. 9, pp. 5584–5591, 1999. View at Google Scholar · View at Scopus
  20. T. Kanto, M. Inoue, H. Miyatake et al., “Reduced numbers and impaired ability of myeloid and plasmacytoid dendritic cells to polarize T helper cells in chronic hepatitis C virus infection,” Journal of Infectious Diseases, vol. 190, no. 11, pp. 1919–1926, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  21. I. Itose, T. Kanto, N. Kakita et al., “Enhanced ability of regulatory T cells in chronic hepatitis C patients with persistently normal alanine aminotransferase levels than those with active hepatitis,” Journal of Viral Hepatitis, vol. 16, no. 12, pp. 844–852, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  22. D. R. Nelson, C. G. Marousis, G. L. Davis et al., “The role of Hepatitis C virus-specific cytotoxic T lymphocytes in chronic hepatitis C,” Journal of Immunology, vol. 158, no. 3, pp. 1473–1481, 1997. View at Google Scholar · View at Scopus
  23. D. R. Nelson, C. G. Marousis, T. Ohno, G. L. Davis, and J. Y. N. Lau, “Intrahepatic hepatitis C virus-specific cytotoxic T lymphocyte activity and response to interferon alfa therapy in chronic hepatitis C,” Hepatology, vol. 28, no. 1, pp. 225–230, 1998. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  24. C. A. Schirren, M. C. Jung, J. T. Gerlach et al., “Liver-derived hepatitis C virus (HCV)-specific CD4(+) T cells recognize multiple HCV epitopes and produce interferon gamma,” Hepatology, vol. 32, no. 3, pp. 597–603, 2000. View at Google Scholar · View at Scopus
  25. N. Kuzushita, N. Hayashi, T. Moribe et al., “Influence of HLA haplotypes on the clinical courses of individuals infected with hepatitis C virus,” Hepatology, vol. 27, no. 1, pp. 240–244, 1998. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  26. C. Renou, P. Halfon, S. Pol et al., “Histological features and HLA class II alleles in hepatitis C virus chronically infected patients with persistently normal alanine aminotransferase levels,” Gut, vol. 51, no. 4, pp. 585–590, 2002. View at Publisher · View at Google Scholar · View at Scopus
  27. Y. Kondo, K. Kobayashi, T. Kobayashi et al., “Distribution of the HLA class I allele in chronic hepatitis C and its association with serum ALT level in chronic hepatitis C,” Tohoku Journal of Experimental Medicine, vol. 201, no. 2, pp. 109–117, 2003. View at Publisher · View at Google Scholar · View at Scopus
  28. K. Yoshizawa, M. Ota, S. Saito et al., “Long-term follow-up of hepatitis C virus infection: HLA class II loci influences the natural history of the disease,” Tissue Antigens, vol. 61, no. 2, pp. 159–165, 2003. View at Google Scholar · View at Scopus
  29. R. B. Yu, X. Hong, W. L. Ding et al., “The association between the genetic polymorphism of HLA-DQA1, DQB1, and DRB1 and serum alanine aminotransferase levels in chronic hepatitis C in the Chinese population,” Journal of Gastroenterology and Hepatology, vol. 23, no. 9, pp. 1394–1402, 2008. View at Publisher · View at Google Scholar · View at PubMed
  30. C. Z. Li, N. Kato, J. H. Chang et al., “Polymorphism of OAS-1 determines liver fibrosis progression in hepatitis C by reduced ability to inhibit viral replication,” Liver International, vol. 29, no. 9, pp. 1413–1421, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  31. Q. J. Gao, D. W. Liu, S. Y. Zhang et al., “Polymorphisms of some cytokines and chronic hepatitis B and C virus infection,” World Journal of Gastroenterology, vol. 15, no. 44, pp. 5610–5619, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. C. Y. Dai, W. L. Chuang, L. P. Lee et al., “Associations of tumour necrosis factor alpha promoter polymorphisms at position -308 and -238 with clinical characteristics of chronic hepatitis C,” Journal of Viral Hepatitis, vol. 13, no. 11, pp. 770–774, 2006. View at Publisher · View at Google Scholar · View at PubMed
  33. C. A. Goulding, R. McManus, A. Murphy et al., “The CCR5-Δ32 mutation: impact on disease outcome in individuals with hepatitis C infection from a single source,” Gut, vol. 54, no. 8, pp. 1157–1161, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  34. S. Mochida, M. Hashimoto, A. Matsui et al., “Genetic polymorphims in promoter region of osteopontin gene may be a marker reflecting hepatitis activity in chronic hepatitis C patients,” Biochemical and Biophysical Research Communications, vol. 313, no. 4, pp. 1079–1085, 2004. View at Publisher · View at Google Scholar · View at Scopus
  35. Z. Ben-Ari, O. Pappo, T. Druzd et al., “Role of cytokine gene polymorphism and hepatic transforming growth factor β1 expression in recurrent hepatitis C after liver transplantation,” Cytokine, vol. 27, no. 1, pp. 7–14, 2004. View at Publisher · View at Google Scholar · View at PubMed
  36. K. Promrat, D. H. McDermott, C. M. Gonzalez et al., “Associations of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C,” Gastroenterology, vol. 124, no. 2, pp. 352–360, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  37. Z. Abbas and T. Moatter, “Interleukin (IL) 1beta and IL-10 gene polymorphism in chronic hepatitis C patients with normal or elevated alanine aminotransferase levels,” The Journal of the Pakistan Medical Association, vol. 53, no. 2, pp. 59–62, 2003. View at Google Scholar · View at Scopus
  38. Y. Tanaka, N. Nishida, M. Sugiyama et al., “Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C,” Nature Genetics, vol. 41, no. 10, pp. 1105–1109, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  39. J. H. Li, X. Q. Lao, H. L. Tillmann et al., “Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection,” Hepatology, vol. 51, no. 6, pp. 1904–1911, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  40. H. Abe, H. Ochi, T. Maekawa et al., “A common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients,” Journal of Hepatology, vol. 53, no. 3, pp. 439–443, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  41. E. A. Kurt-Jones, L. Popova, L. Kwinn et al., “Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus,” Nature Immunology, vol. 1, no. 5, pp. 398–401, 2000. View at Google Scholar · View at Scopus
  42. L. Alexopoulou, A. C. Holt, R. Medzhitov, and R. A. Flavell, “Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3,” Nature, vol. 413, no. 6857, pp. 732–738, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  43. A. Breiman, N. Grandvaux, R. Lin et al., “Inhibition of RIG-I-dependent signaling to the interferon pathway during hepatitis C virus expression and restoration of signaling by IKKε,” Journal of Virology, vol. 79, no. 7, pp. 3969–3978, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  44. T. Saito, D. M. Owen, F. Jiang, J. Marcotrigiano, and M. Gale, “Innate immunity induced by composition-dependent RIG-I recognition of hepatitis C virus RNA,” Nature, vol. 454, no. 7203, pp. 523–527, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  45. M. Otsuka, N. Kato, M. Moriyama et al., “Interaction between the HCV NS3 protein and the host TBK1 protein leads to inhibition of cellular antiviral responses,” Hepatology, vol. 41, no. 5, pp. 1004–1012, 2005. View at Publisher · View at Google Scholar · View at PubMed
  46. D. Séne, F. Levasseur, M. Abel et al., “Hepatitis C virus (HCV) evades NKG2D-dependent NK cell responses through NS5A-mediated imbalance of inflammatory cytokines,” PLoS Pathogens, vol. 6, no. 11, Article ID e1001184, 2010. View at Publisher · View at Google Scholar · View at PubMed
  47. S. Crotta, M. Brazzoli, D. Piccioli, N. M. Valiante, and A. Wack, “Hepatitis C virions subvert natural killer cell activation to generate a cytokine environment permissive for infection,” Journal of Hepatology, vol. 52, no. 2, pp. 183–190, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  48. J. C. Yoon, M. Shiina, G. Ahlenstiel, and B. Rehermann, “Natural killer cell function is intact after direct exposure to infectious hepatitis C virions,” Hepatology, vol. 49, no. 1, pp. 12–21, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  49. L. Golden-Mason, L. Madrigal-Estebas, E. McGrath et al., “Altered natural killer cell subset distributions in resolved and persistent hepatitis C virus infection following single source exposure,” Gut, vol. 57, no. 8, pp. 1121–1128, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  50. C. Morishima, D. M. Paschal, C. C. Wang et al., “Decreased NK cell frequency in chronic hepatitis C does not affect ex vivo cytolytic killing,” Hepatology, vol. 43, no. 3, pp. 573–580, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  51. M. J. Koziel, “NK cells: natural born killers in the conflict between humans and HCV,” Hepatology, vol. 43, no. 3, pp. 395–397, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  52. L. Golden-Mason and H. R. Rosen, “Natural killer cells: primary target for hepatitis C virus immune evasion strategies?” Liver Transplantation, vol. 12, no. 3, pp. 363–372, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  53. T. Takehara and N. Hayashi, “Natural killer cells in hepatitis C virus infection: from innate immunity to adaptive immunity,” Clinical Gastroenterology and Hepatology, vol. 3, no. 10, supplement 2, pp. S78–S81, 2005. View at Publisher · View at Google Scholar · View at Scopus
  54. A. Dolganiuc, S. Oak, K. Kodys et al., “Hepatitis C core and nonstructural 3 proteins trigger toll-like receptor 2-mediated pathways and inflammatory activation,” Gastroenterology, vol. 127, no. 5, pp. 1513–1524, 2004. View at Publisher · View at Google Scholar · View at Scopus
  55. S. M. Riordan, N. A. Skinner, J. Kurtovic et al., “Toll-like receptor expression in chronic hepatitis C: correlation with pro-inflammatory cytokine levels and liver injury,” Inflammation Research, vol. 55, no. 7, pp. 279–285, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  56. T. Abe, Y. Kaname, I. Hamamoto et al., “Hepatitis C virus nonstructural protein 5A modulates the toll-like receptor-MyD88-dependent signaling pathway in macrophage cell lines,” Journal of Virology, vol. 81, no. 17, pp. 8953–8966, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  57. M. J. Koziel, D. K. H. Wong, D. Dudley, M. Houghton, and B. D. Walker, “Hepatitis C virus—Specific cytolytic T lymphocyte and T helper cell responses in seronegative persons,” Journal of Infectious Diseases, vol. 176, no. 4, pp. 859–866, 1997. View at Google Scholar · View at Scopus
  58. M. J. Koziel, “The role of immune responses in the pathogenesis of hepatitis C virus infection,” Journal of Viral Hepatitis, vol. 4 ,supplement 2, pp. 31–41, 1997. View at Google Scholar · View at Scopus
  59. C. M. Rice and C. M. Walker, “Hepatitis C virus-specific T lymphocyte responses,” Current Opinion in Immunology, vol. 7, no. 4, pp. 532–538, 1995. View at Publisher · View at Google Scholar · View at Scopus
  60. M. E. Cramp, S. Rossol, S. Chokshi, P. Carucci, R. Williams, and N. V. Naoumov, “Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C,” Gastroenterology, vol. 118, no. 2, pp. 346–355, 2000. View at Google Scholar · View at Scopus
  61. F. Akyüz, N. Polat, S. Kaymakoglu et al., “Intrahepatic and peripheral T-cell responses in genotype 1b hepatitis C virus-infected patients with persistently normal and elevated aminotransferase levels,” World Journal of Gastroenterology, vol. 11, no. 45, pp. 7188–7191, 2005. View at Google Scholar · View at Scopus
  62. S. Hori, T. Nomura, and S. Sakaguchi, “Control of regulatory T cell development by the transcription factor Foxp3,” Science, vol. 299, no. 5609, pp. 1057–1061, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  63. N. A. Marshall, M. A. Vickers, and R. N. Barker, “Regulatory T cells secreting IL-10 dominate the immune response to EBV latent membrane protein 1,” Journal of Immunology, vol. 170, no. 12, pp. 6183–6189, 2003. View at Google Scholar · View at Scopus
  64. A. Ulsenheimer, J. T. Gerlach, N. H. Gruener et al., “Detection of functionally altered hepatitis C virus-specific CD4+ T cells in acute and chronic hepatitis C,” Hepatology, vol. 37, no. 5, pp. 1189–1198, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  65. M. W. Beilharz, L. M. Sammels, A. Paun et al., “Timed ablation of regulatory CD4+ T cells can prevent murine AIDS progression,” Journal of Immunology, vol. 172, no. 8, pp. 4917–4925, 2004. View at Google Scholar · View at Scopus
  66. Y. Kondo, Y. Ueno, K. Kobayashi et al., “Hepatitis B virus replication could enhance regulatory T cell activity by producing soluble heat shock protein 60 from hepatocytes,” Journal of Infectious Diseases, vol. 202, no. 2, pp. 202–213, 2010. View at Publisher · View at Google Scholar · View at PubMed
  67. Y. Kondo, K. Kobayashi, Y. Ueno et al., “Mechanism of T cell hyporesponsiveness to HBcAg is associated with regulatory T cells in chronic hepatitis B,” World Journal of Gastroenterology, vol. 12, no. 27, pp. 4310–4317, 2006. View at Google Scholar · View at Scopus
  68. F. Bolacchi, A. Sinistro, C. Ciaprini et al., “Increased hepatitis C virus (HCV)-specific CD4+CD25+ regulatory T lymphocytes and reduced HCV-specific CD4+ T cell response in HCV-infected patients with normal versus abnormal alanine aminotransferase levels,” Clinical and Experimental Immunology, vol. 144, no. 2, pp. 188–196, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  69. R. Marinho, R. Pinto, M. L. Santos, and M. C. De Moura, “Evidence for prostaglandin-producing supressor cells in HCV patients with normal ALT,” Digestive Diseases and Sciences, vol. 47, no. 3, pp. 556–561, 2002. View at Publisher · View at Google Scholar · View at Scopus
  70. R. N. Germain, “MHC-dependent antigen processing and peptide presentation: providing ligands for T lymphocyte activation,” Cell, vol. 76, no. 2, pp. 287–299, 1994. View at Publisher · View at Google Scholar · View at Scopus
  71. S. Sadegh-Nasseri, L. J. Stern, D. C. Wiley, and R. N. Germain, “MHC class II function preserved by low-affinity peptide interactions preceding stable binding,” Nature, vol. 370, no. 6491, pp. 647–650, 1994. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  72. P. C. Doherty and R. M. Zinkernagel, “Enhanced immunological surveillance in mice heterozygous at the H-2 gene complex,” Nature, vol. 256, no. 5512, pp. 50–52, 1975. View at Publisher · View at Google Scholar · View at Scopus
  73. M. Carrington, G. W. Nelson, M. P. Martin et al., “HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage,” Science, vol. 283, no. 5408, pp. 1748–1752, 1999. View at Publisher · View at Google Scholar · View at Scopus
  74. A. Mangia, R. Santoro, M. Piattelli et al., “IL-10 haplotypes as possible predictors of spontaneous clearance of HCV infection,” Cytokine, vol. 25, no. 3, pp. 103–109, 2004. View at Publisher · View at Google Scholar · View at Scopus
  75. N. Paladino, H. Fainboim, G. Theiler et al., “Gender susceptibility to chronic hepatitis C virus infection associated with interleukin 10 promoter polymorphism,” Journal of Virology, vol. 80, no. 18, pp. 9144–9150, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  76. H. Abe, C. N. Hayes, H. Ochi et al., “IL28 variation affects expression of interferon stimulated genes and peg-interferon and ribavirin therapy,” Journal of Hepatology, vol. 54, no. 6, pp. 1094–1101, 2011. View at Publisher · View at Google Scholar · View at PubMed